Navigation Links
FDA: Byetta Label Revised to Include Safety Information on Possible Kidney Problems
Date:11/2/2009

SILVER SPRING, Md., Nov. 2 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today acted on new safety information about possible kidney function problems, including kidney failure, in patients taking Byetta (exenatide), a drug used to treat Type 2 diabetes.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

From April 2005 through October 2008, the FDA received 78 reports of problems with kidney function in patients using Byetta. Some cases occurred in patients with pre-existing kidney disease or in patients with one or more risk factors for developing kidney problems.

Nearly 7 million prescriptions for Byetta were dispensed between April 2005 and September 2008. The 78 cases represent a small percentage of the total number of patients using the drug to control blood sugar (glucose) levels.

The most common side effects associated with Byetta include nausea, vomiting, and diarrhea. These side effects may have contributed to the development of altered kidney function. Kidney malfunction can result in a build-up of waste products in the blood, leading to serious illness or life-threatening conditions.

"Health care professionals and patients taking Byetta should pay close attention to any signs or symptoms of kidney problems," said Amy Egan, M.D. M.P.H., of the Division of Metabolism and Endocrinology Products at the FDA's Center for Drug Evaluation and Research. "Patients also should be aware that problems with kidney function could lead to changes in urine color, frequency of urination or the amount of urine, unexplained swelling of the hands or feet, fatigue, changes in appetite or digestion, or dull ache in mid to lower back."

Patients who experience any of these symptoms should immediately discuss them with their health care professional.

To help health care professionals and pat
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Monotherapy BYETTA(R) (exenatide) Injection Study Results Presented at ADA 2008 Showed Adults with Type 2 Diabetes Experienced Improved Glycemic Control and Weight Loss
2. Amylin Pharmaceuticals and Eli Lilly and Company Statement on FDAs BYETTA(R) (Exenatide) Injection Update
3. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
4. Proteolix Initiates Multicenter Open-label Study of the Safety and Activity of Carfilzomib in Subjects With Relapsed Solid Tumors
5. Statement by US Oncology on FDA Label on Erythropoiesis Stimulating Agents (ESAs)
6. Totality of Available Data Reaffirms PROCRIT(R) (Epoetin alfa) Is Safe and Effective When Used Appropriately as Labeled to Treat Chemotherapy-Induced Anemia
7. FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
8. Cephalon Receives Complete Response Letter Regarding Request for Expanded FENTORA Label for Non-Cancer Breakthrough Pain
9. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
10. Covance Announces Integrated Radiolabeled Clinical Pharmacology Studies
11. Schering-Plough Reports Long-Term Vicriviroc Data From Phase II Open-Label Extension Study in Treatment-Experienced HIV-Infected Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/17/2013)... Conn. , May 17, 2013 /PRNewswire-iReach/ -- ... and recombinant proteins, is placing renewed emphasis on ... the rise as a number of factors are ... for pharmaceutical makers and their delivery device partners ... previously refractory conditions, the growing trend toward self-administration ...
(Date:5/17/2013)... 17, 2013  Boehringer Ingelheim will contribute to ... the American Thoracic Society International Conference (ATS 2013) ... 17 – 22. Data will highlight ... treatment of chronic obstructive pulmonary disease (COPD) [Spiriva® ... investigational compounds for asthma, idiopathic pulmonary fibrosis (IPF) ...
(Date:5/17/2013)... (EURONEXT: SAN and NYSE: SNY ) announced today ... examining the selective JAK2 inhibitor SAR302503 for myelofibrosis (MF), ... primary endpoint assessed the proportion of patients achieving >/=35% ... previous trials, the most common adverse events were anemia, ... at an upcoming medical congress. MF ...
Breaking Medicine Technology:Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 2Pharmaceutical Makers and Delivery Device Partners Rethink Delivery Technologies - New Report Examines this Evolving Segment 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 2Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 3Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 4Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 5Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 6Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 7Boehringer Ingelheim to Present 17 Abstracts at the Annual American Thoracic Society International Conference 8Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 2Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 3Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 4Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 5Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis 6
... BOZEN, SUD-TIROL, Italy , July 27, 2010 ... assets from, Italy -based MEDarchiver S.r.l. and Biomedical Technology Consulting S.r.l.,merging ... market, and conducting a re-organization of its,Executive Management, expecting to close ... , , ...
... Sysmex America, Inc., a leading medical diagnostic ... to debut its expanded cell image analysis portfolio during ... Conference and Clinical Lab Expo July 25 - ... DM1200 and DM96 systems for the mid-size to larger ...
Cached Medicine Technology:Health Robotics Surpasses 100 Installations Milestone and Acquires Two I.V. Room of the Future Partner Companies 2Health Robotics Surpasses 100 Installations Milestone and Acquires Two I.V. Room of the Future Partner Companies 3Health Robotics Surpasses 100 Installations Milestone and Acquires Two I.V. Room of the Future Partner Companies 4Sysmex America to Launch Complete Cell Image Analysis Portfolio at AACC 2Sysmex America to Launch Complete Cell Image Analysis Portfolio at AACC 3
(Date:5/19/2013)... Rockford, IL (PRWEB) May 19, 2013 Beginning ... Rock River Valley Blood Center (RRVBC) will feature “Hot Dog ... and Belvidere. RRVBC will provide hot dogs and all ... feature ice-cold slushies each day throughout the summer. “Donors are ... to maintain a stable and adequate blood supply. This ...
(Date:5/19/2013)... 2013 HealthEconomics.Com , the global ... to unveil a new and exciting service: HE-Xpo: a ... powerful array of real-time communication tools to expand their ... abroad. , HE-Xpo is powered by OnStream Media’s ... and feel of being at a physical trade show, ...
(Date:5/19/2013)... 2013 The Da Vinci robot lawyers ... in the nation’s first trial involving a Da Vinci ... State Superior Court, was filed by the widow of ... complications in a robot-assisted prostate removal, according to a ... robotic surgery lawsuit alleges those complication’s hastened his ...
(Date:5/18/2013)... 18, 2013 Daily Gossip issued a press ... review on their page. John Colston, Daily Gossip’s spokesperson, told ... Hadsall’s revolutionizing 14-Day Rapid Fat Loss Plan . ... carbs are healthy at a time when nutritionists and fat ... caloric products. , The diet is based on the ...
(Date:5/18/2013)... American Gastroenterological Association (AGA) Research Foundation is pleased ... honorees are outstanding young gastroenterologists working toward independent ... with this award, their research time will be ... future of our field. AGA is committed to ... for promising research developments and new therapies," said ...
Breaking Medicine News(10 mins):Health News:Hot Dog Wednesdays and Ice Cold Slushies Return to Rock River Valley Blood Center for the Summer 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 2Health News:HealthEconomics.Com Announces HE-Xpo, a New Virtual Trade Show Devoted to Healthcare Value and Market Access 3Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 2Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 3Health News:Da Vinci Surgical Robot Lawyers at Wright & Schulte LLC Note Recent Developments in Da Vinci Robot Lawsuit Trial 4Health News:AGA Research Foundation Research Scholar Awards advance the work of promising gastroenterologists 2
... , ... ... ... ...
... ... role , ... February 25, 2010 -- LocumTenens.com has named Lisa Kaeck as Executive Vice ... of service at LocumTenens.com., , , , ,A founding partner of LocumTenens.com, Kaeck has more ...
... ... ... ... ...
... , ... ... , , ... ...
... ... ... ... Outlawing Health Insurance Monopolies Would Be Good for Doctors, Patients , ...
... cancer patients receiving induction chemotherapy followed by radiation to ... disability and almost half experienced no eating or swallowing ... presented at the Multidisciplinary Head and Neck Cancer Symposium, ... removal with permanent tracheotomy is the current standard treatment ...
Cached Medicine News:Health News:Good Parenting Triumphs Over Prenatal Stress 2Health News:Good Parenting Triumphs Over Prenatal Stress 3Health News:Good Parenting Triumphs Over Prenatal Stress 4Health News:Good Parenting Triumphs Over Prenatal Stress 5Health News:Good Parenting Triumphs Over Prenatal Stress 6Health News:LocumTenens.com Names Lisa Kaeck Executive Vice President 2Health News:Highmark Inc. Prepares Now for the Diversity Boom Ahead 2Health News:Highmark Inc. Prepares Now for the Diversity Boom Ahead 3Health News:Highmark Inc. Prepares Now for the Diversity Boom Ahead 4Health News:Pelosi Remarks at Bipartisan Meeting at Blair House on Health Insurance Reform 2Health News:Pelosi Remarks at Bipartisan Meeting at Blair House on Health Insurance Reform 3Health News:Pelosi Remarks at Bipartisan Meeting at Blair House on Health Insurance Reform 4Health News:Pelosi Remarks at Bipartisan Meeting at Blair House on Health Insurance Reform 5Health News:Pelosi Remarks at Bipartisan Meeting at Blair House on Health Insurance Reform 6Health News:Pelosi Remarks at Bipartisan Meeting at Blair House on Health Insurance Reform 7Health News:Doctors Applaud House Vote to Remove Anti-Trust Exemption for Health Insurers 2Health News:Doctors Applaud House Vote to Remove Anti-Trust Exemption for Health Insurers 3
... The 5mm AEM Laparoscopic Instruments incorporate a ... Instruments are shielded and monitored to prevent ... the instrument caused by insulation failure or ... The protective shield built into all AEM ...
... Featured Products are kept ... and are offered as ... regular or extra long ... with insulation, flush ports, ...
... The 5mm AEM Laparoscopic Instruments incorporate ... AEM Instruments are shielded and monitored to ... of the instrument caused by insulation failure ... risk. The protective shield built into all ...
... Instruments incorporate a layered design unique in ... monitored to prevent stray electrosurgical burns along ... insulation failure or capacitive coupling; a well-documented ... into all AEM Instruments provides a neutral ...
Medicine Products: